We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Could Diagnose Schizophrenia and Other Disorders

By LabMedica International staff writers
Posted on 22 Feb 2017
Schizophrenia is a chronic, severe mental disorder that affects approximately 1% of the adult population in the USA and influences how a person thinks, feels, and behaves. More...
The onset of symptoms usually begins between ages 16 and 30. Symptoms can range from visual and auditory hallucinations and movement disorders to difficulty beginning and sustaining activities.

The diagnosis of schizophrenia and similar disorders requires a thorough psychological evaluation and a comprehensive medical exam to rule out other conditions. A patient may be evaluated for six or more months before receiving a diagnosis and beginning treatment, particularly if he or she shows only early signs of the disorder.

Scientists at the University of Maryland have developed a blood test that could help doctors more quickly diagnose schizophrenia and other disorders. They used a discovery-driven approach based on the assumptions that chemical biomarkers relating to oxidative stress could be found in blood, and that they could be measured by common electrochemical instruments.

The team used performed an initial clinical evaluation using serum from 10 people diagnosed with schizophrenia, a mental health disorder that is increasingly linked to oxidative stress. The scientists used an iridium salt, potassium hexachloroiridate (K2IrCl6), to probe serum for reducing activities that can transfer electrons to iridium and thus generate detectable optical and electrochemical signals. They showed that this Ir-reducing assay can detect various biological reductants and is especially sensitive to glutathione (GSH) compared to alternative assays.

The new testing method was able to correctly differentiate the samples of those who had been diagnosed with schizophrenia from those who had no history of the disorder. Deana L. Kelly PharmD, BCPP, a professor of psychiatry and a co-author of study said, “Much emerging data suggests that schizophrenia and other psychiatric disorders may be due, in part, to inflammation and oxidative stress abnormalities. Current methods for measuring these potential biomarkers are not standardized and have many flaws.” The study was published on February 7, 2017, in the journal Analytical Chemistry.


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.